corticosteroids - for COVID-19 severe or critically method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.77 [0.60, 0.99]< 165%6 studies (6 / -)97.7 %highnot evaluable lowcrucial-
deaths (time to event analysis only) 0.29 [0.15, 0.56]< 10%1 study (1 / -)100.0 %highnot evaluable lowcrucial-
clinical improvement 1.16 [0.84, 1.60]> 10%2 studies (2 / -)81.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.16 [0.84, 1.60]> 10%2 studies (2 / -)81.0 %some concernnot evaluable moderateimportant-
clinical worsening 0.66 [0.43, 1.02]< 10%1 study (1 / -)96.9 %some concernnot evaluable moderateimportant-
death or ventilation 0.71 [0.37, 1.35]< 10%1 study (1 / -)85.3 %lownot evaluable highimportant-
ventilationno RCT reported results for this endpoint, but 1 observational studies are available. Clear RCT filter to include observational studies
ICU admissionno RCT reported results for this endpoint, but 1 observational studies are available. Clear RCT filter to include observational studies

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 91 91